Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia

Keyphrases

• Abl Kinase 66%
• Adverse Effects 33%
• Adverse Events 33%
• BCR-ABL 33%
• Chronic Myeloid Leukemia 100%
• Clinical Management 33%
• Clinical Response 33%
• Complete Cytogenetic Response 33%
• Dasatinib 33%
• Imatinib 100%
• Imatinib Resistance 33%
• Inhibitory Activity 33%
• Kinase Domain 33%
• Nilotinib 33%
• Patient's Will 33%
• Practical Management 100%
• Second-generation TKI 33%
• Therapeutic Approaches 33%
• Toxicity Management 100%
• Treatment Interruption 33%
• Tyrosine Kinase Inhibitor 100%
• Tyrosine Kinase Inhibitor Therapy 33%

Medicine and Dentistry

• Abelson Kinase 66%
• Adverse Event 66%
• Chronic Myelogenous Leukemia 100%
• Clinical Management 33%
• Dasatinib 33%
• Disease 33%
• Imatinib 100%
• Imatinib Resistance 33%
• Nilotinib 33%
• Treatment Interruption 33%
• Tyrosine-Kinase Inhibitor 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Abelson Kinase 50%
• Adverse Event 50%
• Chronic Myeloid Leukemia 100%
• Dasatinib 25%
• Disease 25%
• Imatinib 100%
• Nilotinib 25%
• Protein Tyrosine Kinase Inhibitor 100%